Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma

doi:10.3748/wjg.v30.i19.2512

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1004)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

783

Figures (1-2)

Tables (1-1)

Sum=896

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=55

May 21, 2024 (publication date) through Jun 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 21, 2024; 30(19): 2512-2522
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512

Open in New Tab Full Size Figure Download Figure

Figure 1 Drugs available for systemic therapy classified according to their mechanism of action, indicating by arrows and colors the main drug combinations studied. ¹Immunotherapy. PD1: Programmed cell death protein 1; PDL1: Programmed death-ligand 1; CTLA4: Cytotoxic T-lymphocyte associated protein 4; VEGF: Vascular endothelial growth factor.

Open in New Tab Full Size Figure Download Figure

Figure 2 Median overall survival shown in clinical trials by drugs approved as first-line systemic therapy, compared with sorafenib. IMbrave150 analyzed atezolizumab + bevalizumab. HIMALAYA investigated durvalumab + tremelimumab.

Citation: Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, Diago M. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma. World J Gastroenterol 2024; 30(19): 2512-2522
URL: https://www.wjgnet.com/1007-9327/full/v30/i19/2512.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i19.2512